Additional file 1 of Simultaneous targeted and discovery-driven clinical proteotyping using hybrid-PRM/DIA

Additional file 1: Fig. S1. MSxPRM performance of hybrid-PRM/DIA on tumor-associated antigen peptides without HeLa background matrix. Fig. S2. Hybrid-PRM/DIA performance on TAA peptides in terms of CVs (MSxPRM) and protein group identifications (DIA). Fig. S3. Scheduling windows for monitoring 60, 120 or 179 targets simultaneously in MSxPRM. Fig. S4. Extracted level-1/level-2 melanoma markers from a DIA data matrix of 95 melanoma patient samples. Fig. S5. Calibration curve of the PMEL peptide NQDWLGVSR